CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

-CPX-351 will be provided by Jazz Pharmaceuticals

"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"

"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"

"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"